Cox regression analyses of factors potentially associated with neutrophil engraftment, treatment-related mortality, and survival after unrelated donor UCB transplantation
| Variable . | Relative risk (95% CI) . | P . |
|---|---|---|
| Neutrophil recovery | Model χ2= 25.6, P < .01 | |
| CD34 dose (× 105/kg) | ||
| Less than 1.7 | 1.0 | |
| 1.7-2.7 | 1.7 (0.8-3.6) | .14 |
| 2.8-5.4 | 2.6 (1.3-5.4) | < .01 |
| More than 5.4 | 4.7 (2.2-9.8) | < .01 |
| Growth factor | ||
| No | 1.0 | .09 |
| Yes | 3.4 (0.8-2.1) | |
| HLA match | ||
| 6/6 and 5/6 | 1.0 | NS |
| 4/6 | 0.9 (0.6-1.6) | |
| Acute GVHD | Model χ2 = 0.9, NS | |
| CD3 dose (× 106/kg) | ||
| Less than 8 | 1.0 | |
| 8 or more | 0.7 (0.2-1.9) | NS |
| Age (by decade) | 1.0 (0.98-1.03) | NS |
| HLA match | ||
| 6/6 and 5/6 | 1.0 | |
| 4/6 | 1.2 (0.5-2.7) | NS |
| Treatment-related mortality | Model (χ2 = 29.2, P < .01) | |
| CD34 dose (× 105/kg) | ||
| 1.7 or less | 1.0 | |
| More than 1.7 | 0.2 (0.1-0.5) | < .01 |
| Age (by decade) | 1.3 (1.0-1.6) | .03 |
| Grade III-IV acute GVHD | ||
| No | 1.0 | |
| Yes | 4.4 (1.7-11.4) | < .01 |
| HLA match | ||
| 6/6 and 5/6 | 1.0 | |
| 4/6 | 1.6 (0.6-3.9) | .34 |
| Survival | Model χ2 = 22.8, P< .01) | |
| CD34 dose (× 105/kg) | ||
| 1.7 or less | 1.0 | |
| More than 1.7 | 0.3 (0.1-0.5) | < .01 |
| Grade III-IV acute GVHD | ||
| No | 1.0 | |
| Yes | 3.5 (1.5-7.9) | < .01 |
| HLA match | ||
| 6/6 and 5/6 | 1.0 | |
| 4/6 | 2.4 (1.2-4.7) | .01 |
| Variable . | Relative risk (95% CI) . | P . |
|---|---|---|
| Neutrophil recovery | Model χ2= 25.6, P < .01 | |
| CD34 dose (× 105/kg) | ||
| Less than 1.7 | 1.0 | |
| 1.7-2.7 | 1.7 (0.8-3.6) | .14 |
| 2.8-5.4 | 2.6 (1.3-5.4) | < .01 |
| More than 5.4 | 4.7 (2.2-9.8) | < .01 |
| Growth factor | ||
| No | 1.0 | .09 |
| Yes | 3.4 (0.8-2.1) | |
| HLA match | ||
| 6/6 and 5/6 | 1.0 | NS |
| 4/6 | 0.9 (0.6-1.6) | |
| Acute GVHD | Model χ2 = 0.9, NS | |
| CD3 dose (× 106/kg) | ||
| Less than 8 | 1.0 | |
| 8 or more | 0.7 (0.2-1.9) | NS |
| Age (by decade) | 1.0 (0.98-1.03) | NS |
| HLA match | ||
| 6/6 and 5/6 | 1.0 | |
| 4/6 | 1.2 (0.5-2.7) | NS |
| Treatment-related mortality | Model (χ2 = 29.2, P < .01) | |
| CD34 dose (× 105/kg) | ||
| 1.7 or less | 1.0 | |
| More than 1.7 | 0.2 (0.1-0.5) | < .01 |
| Age (by decade) | 1.3 (1.0-1.6) | .03 |
| Grade III-IV acute GVHD | ||
| No | 1.0 | |
| Yes | 4.4 (1.7-11.4) | < .01 |
| HLA match | ||
| 6/6 and 5/6 | 1.0 | |
| 4/6 | 1.6 (0.6-3.9) | .34 |
| Survival | Model χ2 = 22.8, P< .01) | |
| CD34 dose (× 105/kg) | ||
| 1.7 or less | 1.0 | |
| More than 1.7 | 0.3 (0.1-0.5) | < .01 |
| Grade III-IV acute GVHD | ||
| No | 1.0 | |
| Yes | 3.5 (1.5-7.9) | < .01 |
| HLA match | ||
| 6/6 and 5/6 | 1.0 | |
| 4/6 | 2.4 (1.2-4.7) | .01 |